Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. OBJECTIVE: To evaluate the treatment effect of alemtuzumab on low-contrast vision in relapsing–remitting multiple sclerosis (RRMS) patients. METHODS: This was a pre-defined exploratory analysis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Graves, Jennifer, Galetta, Steven L, Palmer, Jeffrey, Margolin, David H, Rizzo, Marco, Bilbruck, John, Balcer, Laura J
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2013
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3807733/
https://ncbi.nlm.nih.gov/pubmed/23459567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458513475722
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars